Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.

• Main Authors: Niklas K U Koehler, Elke Stransky, Mona Shing, Susanne Gaertner, Mirjam Meyer, Brigitte Schreitmüller, Thomas Leyhe, Christoph Laske, Walter Maetzler, Phillipp Kahle, Maria S Celej, Thomas M Jovin, Andreas J Fallgatter, Anil Batra, Gerhard Buchkremer, Klaus Schott, Elke Richartz-Salzburger
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2013-01-01
• Series: PLoS ONE
• Online Access: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23741358/?tool=EBI

Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against α-synuclein is not well known. We explored serum IgG levels to monomeric α-synuclein in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) with a novel and validated highly sensitive ELISA assay. Antibody levels revealed stark differences in patients compared to healthy subjects and were dependent on diagnosis, disease duration and age. Anti-α-synuclein IgG levels were increased in both patient groups, but in early DLB to a much greater extent than in AD. Increased antibody levels were most evident in younger patients, while with advanced age relatively low levels were observed, similar to healthy individuals, exhibiting stable antibody levels independent of age. Our data show the presence of differentially altered IgG levels against α-synuclein in DLB and AD, which may relate to a disturbed α-synuclein homeostasis triggered by the disease process. These observations may foster the development of novel, possibly preclinical biomarkers and immunotherapeutic strategies that target α-synuclein in neurodegenerative disease.